Cigna and Express Scripts Patient Assurance Program

Cigna and Express Scripts Patient Assurance Program

Ten press releases are discussed below regarding the copay programs offered by various pharmaceutical companies. Most of these articles feature both copay program data and the type of prescription drugs covered. In this regard, the articles provide a mix of the copay programs various pharmaceuticals are using, along with the illnesses they cover and the amount of monetary support these copay programs advance.

Cigna and Express Scripts Patient Assurance Program

• This press release was published on April 23, 2019, by Cigna.
• The article announces a new partnership Cigna formed with Express Scripts to help patients who need insulin to access it at affordable rates. The partnership with insulin manufacturers aims to reduce copayments to $25 at retail purchase.
• This article helps portray the activities of Express Scripts, a pharmacy benefit management company.

  Don't use plagiarised sources.Get your custom essay just from $11/page

  GET CUSTOM PAPER

Titan Pharmaceuticals Partners with Appianrx to Provide Comprehensive Probuphine® Patient Support Services

• This article was published on March 28, 2019, by Titan Pharmaceuticals.
• The article announces Titan’s effort to deliver a comprehensive suite of probuphine (buprenorphine) implant support services to patients through an execution agreement with AppianRX, a specialty healthcare solutions provider.
• The services include the management of benefits verification, authorization and appeals, and copay and patient assistance programs. These services are aimed at improving access to probuphine and making it affordable and readily available.
• This press release shows the activities of Titan Pharmaceuticals regarding its copay and patient assistance program aimed at streamlining access to probuphine treatment at affordable rates.

VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance

• This article was published on May 15, 2019, by HarborPath Direct.
• The article features information regarding a partnership between Vivus and HarborPath Direct to facilitate access to pancreaze for patients not covered. The company aims at making pancreaze accessible to eligible individuals via the Pancreaze Advantage Program and the Vivus Health Platform.
• The copay program facilitated by Vivus seeks to address the critical and growing challenges of patients who are either uninsured or underinsured. Overall, the article helps portray the activities of Vivus in providing a favorable copay system that supports uninsured and underinsured patients.

Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic

• This article was published on May 09, 2019, by Gilead Sciences.
• In this press release, Gilead Sciences discusses its copay coupon support program, which it uses to deliver a bottle of Truvada for PrEP at $0. However, individuals who are not commercially insured can access Truvada for PrEP free of charge via a new CDC-Gilead partnership or Gilead’s Medication Assistance Program.
• The report provides in-depth information regarding Gilead’s efforts in protecting HIV-risk patients by offering PrEP, which is accessible via acopay coupon program, and other patient assistance programs. It also helps portray the activities of Gilead Sciences regarding copay programs.

AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection)

• This press release was published on August 27, 2019, by GlobeNewswire.
• The article discusses AMAG Pharmaceutical’s commitment towards improving access to Vyleesi for eligible premenopausal women with HSDD. It analyzes how eligible women can access the drug via AMAG’s copay assistance program offering the “first four-pack of Vyleesi auto-injectors for $0.”
• Further, the report asserts that under the copay program, women refilling their prescription can do so for a four-pack of Vyleesi at $99 or less. The article helps portray AMAG Pharmaceutical’s activities regarding its copay program.

MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day

• This article was published on January 16, 2019, by MannKind Corporation.
• The press release discusses options MannKind is offering for patients to refill their insulin prescriptions, including its enhanced copay andsavings card program. The program will allow commercially insured patients to fill their prescriptions for $15 at local pharmacies.
• The report also provides this link with more information regarding its copay program. Generally, the press release helps portray the activities of MannKind Corporation regarding its copay program.

Sanofi Expands Insulin Savings Program, but Affordability Still an Issue

• This article was published on April 10, 2019, by BioPharma Dive.
• The press release discusses Sanofi’s copay program, which features copay cards. The company estimates that in 2018, it had about 9,600 patients using the insulin assistance program. Sanofi’s spokesperson said that over “90% of patients using Sanofi copay cards pay only $10 or less per month for their Sanofi insulin.”
• The article helps to portray the activities of Sanofi regardingits copay program. The company further claims that its program has saved patients approximately $10 million since its inception.

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for U.S. Payers and Families

• This press release was published on May 24, 2019, by Novartis.
• The article discusses AveXis’ efforts towards creating “5-year outcomes-based agreements and novel pay-over-time options; Time is Neurons program” for rapid SMA management post-diagnosis. The copay and patient assistance program seek to deliver dedicated and customizable support for Zolgensma patients.
• The plan dubbed OneGene Program will offer solutions such as “answering questions about Zolgensma, verifying reimbursement assistance, and coordinating financial assistance programs for eligible patients.”
• Overall, the article helps portray the activities of AveXis regarding its OneGene Program, a patient assistance and copay program.

Novo Nordisk Announces Half-price, Authorized Generic Insulins

• This article was published on September 9, 2019, by Healio.
• The report shows continued efforts being undertaken by Novo Nordisk to increase the access of insulin to patients who need it via its diabetes patient assistance programs andcopay assistance programs.
• The report shows Novo Nordisk’s activities regarding its copay assistance programs, and collaborations; for instance, it partnered with Walmart since 2000 to provide human insulin for about $25 a vial.
• The press release aims to show Novo Nordisk’s activities regarding copay programs, including its latest move to provide a $99 cash card program for its analogue insulin products.

UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

• This article was published on November 25, 2019, by R. Newswire.
• The press release provides details regarding a copay support program and a patient assistance program provided by UCB to help eligible NAYZILAM
• UCB’s copayment savings card program called NAYZILAM Savings Card will help eligible patients pay only $20 per box of NAYZILAM prescriptions.
• Overall, the article discusses UCB’s copay and savings card program, which shows the activities of UCB regarding copay programs.